InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
April 30, 2024 07:30 ET
|
InflaRx N.V.
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
January 04, 2024 07:00 ET
|
InflaRx N.V.
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90%...
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
September 11, 2023 07:00 ET
|
InflaRx N.V.
SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: Safety and tolerability with no signals of concern over entire dose rangePharmacokinetics (PK): favorable...
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
November 09, 2022 07:40 ET
|
InflaRx N.V.
Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and...
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
January 10, 2022 07:30 ET
|
InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...